Micreos BV, of Wageningen, The Netherlands, said it has developed Staphefekt, a bacteria-killing enzyme, or endolysin, specific to Staphylococcus aureus, which is equally effective in killing methicillin-resistant S. aureus. This is the first endolysin available for human use on intact skin.